37,166 Shares in Kenvue Inc. (NYSE:KVUE) Bought by Brown Financial Advisors

Brown Financial Advisors acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 37,166 shares of the company’s stock, valued at approximately $676,000.

Other hedge funds have also bought and sold shares of the company. Manchester Capital Management LLC raised its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the period. Mather Group LLC. purchased a new stake in Kenvue in the first quarter worth $28,000. Riverview Trust Co bought a new stake in shares of Kenvue during the first quarter worth $33,000. MV Capital Management Inc. boosted its stake in shares of Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after purchasing an additional 642 shares during the period. Finally, Salomon & Ludwin LLC purchased a new stake in Kenvue in the 1st quarter valued at about $33,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on KVUE shares. JPMorgan Chase & Co. increased their price objective on Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. UBS Group increased their price target on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a report on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $22.10.

Kenvue Price Performance

NYSE KVUE opened at $22.79 on Wednesday. The firm’s fifty day simple moving average is $21.50 and its two-hundred day simple moving average is $20.09. The firm has a market capitalization of $43.63 billion, a P/E ratio of 29.21, a P/E/G ratio of 2.92 and a beta of 1.40. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $23.55.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the previous year, the business earned $0.32 EPS. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Analysts forecast that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were given a $0.205 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.